Panacea Biotec’s shares surged more than 4% following news of a significant international milestone. The company has received a Letter of Award from UNICEF to supply bivalent oral polio vaccine (bOPV) over the next four years. As of 2:32 PM, the shares were trading 4.49% higher at Rs 419.00.
The long-term agreement, running from April 1, 2026, to March 31, 2030, will see Panacea Biotec delivering vaccines in both 10-vial and 20-vial presentations. Deliveries are scheduled to begin in the second quarter of 2026 and continue through 2027. The total contract is valued at approximately USD 35.65 million (around ₹315 crore).
UNICEF has stated that details of the award—including the supplier, vaccine type, contract duration, value, and pricing—will be published on its official platform, reflecting the organization’s commitment to transparency.
This international order reinforces Panacea Biotec’s position as a reliable global vaccine supplier. The company also clarified that neither its promoters nor group companies have any interests in UNICEF, and the contract does not constitute a related-party transaction.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
